ASX Share rice
Sun 09 Aug 2020 - 09:26:am (Sydney)

AHZ Share Price

ADMEDUS LTDAHZHealth Care Equipment & Services

AHZ Company Information

Name:

Anteris Technologies Ltd

Sector:

Healthcare

Industry:

Medical Devices

GIC Industry:

Health Care Equipment & Supplies

GIC Sub Industry:

Health Care Supplies

Address:

Toowong Tower Toowong QLD Australia 4066

Phone:

61 1300 550 310

CEO, Pres, MD & Exec. Director:

Mr. Wayne G. Paterson

Chief Financial Officer:

Mr. Matthew McDonnell

Chief Operating Officer:

Mr. David St. Denis

Gen. Counsel:

Ms. Martha Engel

Chief Medical Officer:

Dr. Kiran Bhirangi

Company Overview:

Admedus Limited, a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. It manufactures, distributes, and sells proprietary ADAPT regenerative tissue products; and researches and develops regenerative medicine and immunotherapies. The company was formerly known as Allied Healthcare Group Limited and changed its name to Admedus Limited in November 2013. Admedus Limited is based in Toowong, Australia.

AHZ Share Price Information

Shares Issued:

5.91M

Dividend Yield:

%

Revenue (TTM):

$17.08M

Revenue Per Share (TTM):

$2.89

Earnings per Share:

$-0.053

Profit Margin:

-0.3408

Operating Margin (TTM):

$-1.51

Return On Assets (TTM):

$-0.56

Return On Equity (TTM):

$-0.33

Quarterly Revenue Growth (YOY):

-0.502

Gross Profit(TTM):

$8M

Diluted Earnings Per Share (TTM):

$-0.986

AHZ CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$20.57M

Change To Liabilities:

$-2,255,546

Total Cashflow From Investing Activities:

$20.57M

Net Borrowings:

$710.38K

Net Income:

$-5,819,673

Total Cash From Operating Activities:

$-22,867,298

Depreciation:

$1.23M

Change To Inventory:

$2.03M

Change To Account Receivables:

$-5,204,896

Sale Purchase Of Stock:

$-640,562

Capital Expenditures:

$67.16K

AHZ Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-6,181,382

Net Income:

$-5,819,673

Gross Profit:

$8.30M

Operating Income:

$-25,573,185

Other Operating Expenses:

$0.93M

Interest Expense:

$289.71K

Total Revenue:

$17.08M

Total Operating Expenses:

$33.88M

Cost Of Revenue:

$8.77M

AHZ Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$1.70M

Total Liabilities:

$10.47M

Total Stockholder Equity:

$15.54M

Other Current Liabilities:

$400K

Total Assets:

$26M

Common Stock:

$137.76M

Retained Earnings:

$-119,498,046

Other Liabilities:

$2M

Other Assets:

$729.68K

Cash:

$8.97M

Total Current Liabilities:

$7.30M

Short-Term Debt:

$1.11M

Property - Plant & Equipment:

$2.96M

Net Tangible Assets:

$13.81M

Total Current Assets:

$20.58M

Net Receivables:

$612.91K

Short-Term Investments:

$5.42M

Inventory:

$1.81M

Accounts Payable:

$1.13M

Non Currrent Assets (Other):

$5.42M

Short-Term Investments:

$5.42

Non Current Liabilities (Other):

$1.40M

Non Current Liabilities Total:

$3.17M

AHZ Share Price History

AHZ News

09 Jul, 2020
BRISBANE, Australia and EAGAN, Minn., July 09, 2020 -- Anteris Technologies Limited (ASX:AVR), a structural heart company advancing the DurAVR™ valve, a novel aortic valve.
01 Jun, 2020
Admedus Limited (ASX:AHZ), announced today that it has changed the Company’s name to Anteris Technologies Ltd (“Anteris”). As of May 22, 2020 Anteris, is trading on the Australian Securities Exchange under the ticker AVR. This milestone signifies the completion of Admedus’ restructuring program focused on transitioning to a dedicated structural heart company anchored by ADAPT®, a next generation regenerative bioscaffold platform technology being utilized to address multiple cardiovascular procedures and repairs including, a product (DurAVR™) in development for Transfemoral Aortic Valve Replacement (TAVR) procedures.
12 Apr, 2020
Wayne Paterson has been the CEO of Admedus Limited (ASX:AHZ) since 2016. First, this article will compare CEO...
13 Jan, 2020
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
15 Oct, 2019
Wayne Paterson became the CEO of Admedus Limited (ASX:AHZ) in 2017. First, this article will compare CEO compensation...
13 Oct, 2019
The acquired patches, marketed under the brands CardioCel® and VascuCel®, are processed in a manner that is intended to reduce the risk of calcification.  Annualized 2019 sales of these product lines were $7.1 million, mostly in the US and Europe. Guidance on how this acquisition may affect LeMaitre Vascular’s 2019 revenue, operating income and EPS expectations will be provided at the Company’s Q3 2019 earnings call on October 23, 2019.